GleamWall
中文EN

AMGN AMGEN INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 318154 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.2%
TTM net income YoY34.1%
TTM EPS YoY33.4%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR7.5%

Margins

Gross margin70.9%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
EBITDA margin39.4%

Returns

ROE78.4%
ROA10.1%
ROIC (approx.)19.5%
Asset turnover0.42x

Leverage & solvency

Liabilities / assets85.1%
Debt / equity3.76x
Current ratio1.48x
Interest coverage4.78x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio-2.8%
Payout ratio57.1%
Capex / revenue6.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.37B$10.05B$8.62B$9.87B$9.56B$9.18B$8.15B$9.09B
Cost of revenue$2.79B$2.81B$2.74B$2.98B$3.08B$3.01B$2.97B$3.11B
Gross profit$7.58B$7.24B$5.87B$6.89B$6.47B$6.17B$5.18B$5.97B
R&D expense$2.11B$1.87B$1.72B$2.14B$1.90B$1.74B$1.49B$1.72B
SG&A expense$1.68B$1.75B$1.60B$1.95B$1.72B$1.69B$1.69B$1.88B
Operating income$3.71B$3.51B$2.67B$2.72B$2.53B$2.66B$1.18B$2.31B
Interest expense$653.00M$673.00M$657.00M$653.00M$685.00M$694.00M$723.00M$747.00M
Pretax income$4.69B$2.77B$2.08B$1.51B$3.92B$1.57B$1.97B$782.00M
Income tax$822.00M$393.00M$265.00M$181.00M$705.00M$136.00M$243.00M$155.00M
Net income$3.86B$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627.00M
EBITDA$3.94B$3.74B$3.78B$3.85B$2.76B$2.88B$2.56B$3.71B
EPS (basic)7.144.403.37—5.982.663.22—
EPS (diluted)7.084.373.34—5.932.653.20—
Dividends declared per share2.522.522.522.522.382.382.382.25
Weighted avg. shares (diluted)546.00M544.00M544.00M—542.00M541.00M541.00M—
Balance sheet
Cash & equivalents$13.19B$13.99B$12.04B$9.13B$9.45B$8.03B$8.81B$11.97B
Receivables$10.35B$10.23B$9.14B$9.57B$8.49B$8.70B$8.13B$6.78B
Inventory$6.39B$6.22B$6.19B$6.22B$6.35B$6.58B$6.73B$7.00B
Current assets$34.36B$34.96B$31.48B$29.06B$27.89B$26.73B$26.93B$29.03B
PP&E, net$8.88B$8.55B$8.22B$7.91B$7.22B$6.86B$6.68B$6.54B
Goodwill$18.66B$18.67B$18.67B$18.68B$18.68B$18.67B$18.64B$18.64B
Intangibles$19.54B$20.49B$21.38B$22.28B$23.14B$24.61B$25.72B$27.70B
Total assets$96.05B$95.64B$92.50B$90.59B$90.14B$87.90B$89.37B$91.84B
Current liabilities$23.23B$25.50B$24.95B$25.49B$21.79B$20.48B$23.01B$23.10B
Short-term debt$2.40B$5.45B$5.44B$4.60B$2.15B$2.44B$3.37B$3.55B
Long-term debt$51.61B$51.86B$51.89B$50.01B$52.43B$53.76B$54.01B$56.55B
Total debt$54.01B$57.30B$57.32B$54.60B$54.59B$56.20B$57.38B$60.10B
Total liabilities$81.70B$83.95B$83.31B$81.93B$80.52B$80.47B$83.16B$85.96B
Shareholders' equity$14.35B$11.69B$9.19B$8.66B$9.62B$7.43B$6.21B$5.88B
Net debt$40.82B$43.31B$45.28B$45.48B$45.14B$48.18B$48.57B$48.13B
Shares outstanding540.90M540.60M539.70M538.80M538.50M538.30M537.70M536.90M
Cash flow statement
Operating cash flow$4.24B$4.00B$2.19B$1.60B$4.68B$2.28B$1.39B$4.77B
Capital expenditure$587.00M$513.00M$712.00M$642.00M$436.00M$369.00M$411.00M$371.00M
Free cash flow$3.65B$3.49B$1.48B$961.00M$4.25B$1.91B$980.00M$4.40B
Investing cash flow-$649.00M-$569.00M-$716.00M-$693.00M-$414.00M-$389.00M-$447.00M-$402.00M
Financing cash flow-$4.39B-$1.48B$1.44B-$1.23B-$2.85B-$2.67B-$4.11B-$1.41B
Depreciation & amortization$233.00M$222.00M$1.12B$1.13B$232.00M$220.00M$1.39B$1.40B
Stock-based compensation$128.00M$165.00M$75.00M$125.00M$127.00M$157.00M$85.00M$134.00M
Dividends paid$1.36B$1.36B$1.36B$1.28B$1.28B$1.28B$1.28B$1.21B

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.